Mifepristone in Children With Refractory Cushing's Disease
Study objectives are to obtain safety, pharmacokinetic, and pharmacodynamic data on the effect of mifepristone on glucose metabolism, body weight and the growth-hormone-IGF in children with refractory Cushing's disease.
|Study Design:||Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||An Open-label Study of the Safety, Pharmacokinetics and Pharmacodynamics of Mifepristone in Children With Refractory Cushing's Disease|
- Adverse events [ Time Frame: collected during the12 week study and 4 week follow-up period; up to 16 weeks total. ] [ Designated as safety issue: Yes ]Patients who have received at least 1 dose of mifepristone will be included in the safety evaluations.
|Study Start Date:||August 2013|
|Estimated Primary Completion Date:||December 2016 (Final data collection date for primary outcome measure)|
Daily doses of mifepristone over 84 days.
Other Name: Korlym
The study is being done to examine the effects of a medication called mifepristone in children with Cushing's disease. Since a child's body may absorb and use mifepristone in a different way than adults, it is important to have information about the amount of mifepristone to give children and what will happen to it. Mifepristone has been FDA approved for use only in adults with Cushing's syndrome, and it is important to learn if mifepristone improves the symptoms and signs of Cushing's disease in children. The study is limited to children with Cushing's syndrome due to a pituitary tumor (Cushing's disease) and will not enroll children with Cushing's syndrome due to other causes. The study will investigate how children's bodies absorb and process mifepristone, how it works in children and what effect it has on the use of sugar in the body, on the child's weight and on growth hormone. An important part of the study is to evaluate the side effects of mifepristone in children.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01925092
|Contact: Charalampos Lyssikatos, M.D.||firstname.lastname@example.org|
|United States, Maryland|
|National Institute of Child Health and Human Development (NICHD)||Recruiting|
|Bethesda, Maryland, United States, 20892-1103|
|Contact: Charalampos Lysikatos-Lyssikatos 301-496-1211 email@example.com|
|Principal Investigator: Maya B Lodish, M.D.|